Kare Schultz
Officer, Director at Teva Pharmaceutical Industries Ltd (TEVA)
Kare Schultz has filed 20 insider reports with the SEC since February 2021, as director at Hims & Hers Health, Inc. (HIMS), officer and director at Teva Pharmaceutical Industries Ltd (TEVA) and director at International Flavors & Fragrances Inc (IFF). The latest filing, on August 18, 2026, reports exercise or conversion of a derivative at Hims & Hers Health, Inc. (HIMS).
- Filings
- 20
- Companies
- 3
- Bought on market
- None
- Sold on market
- None
Companies where Kare Schultz is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Directorsince July 2024 | 26,020 | $14.60 | Aug 18, 2026 | ||||
| Officer, Director | 1,542,471 | $39.23 | Nov 2, 2022 | ||||
| Directorsince February 2021 | 1,344 | $79.62 | May 6, 2022 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Aug 14, 2026HIMSDirector Schultz Kare converted options into 6,623 shares, increasing direct ownership by 34% to 26,020 unitsForm 4Exercise or conversion of a derivative
- Aug 12, 2026HIMSSEC Form 4 filed by Director Schultz KareForm 4Grant or award
- Jun 11, 2026HIMSDirector Schultz Kare converted options into 3,656 shares, increasing direct ownership by 23% to 19,397 unitsForm 4Exercise or conversion of a derivative
- Sep 15, 2025HIMSDirector Schultz Kare converted options into 6,623 shares, increasing direct ownership by 73% to 15,741 unitsForm 4Exercise or conversion of a derivative
- Aug 6, 2025HIMSSEC Form 4 filed by Director Schultz KareForm 4Grant or award
- Jun 12, 2025HIMSDirector Schultz Kare converted options into 9,118 sharesForm 4Exercise or conversion of a derivative
- Aug 7, 2024HIMSSEC Form 4 filed by Director Schultz KareForm 4Grant or award
- Jul 16, 2024HIMSKare Schultz became an insiderForm 3New insider
- Nov 1, 2022TEVASEC Form 4: Schultz Kare converted options into 116,389 units of Ordinary Shares, increasing direct ownership by 8% to 1,542,471 unitsForm 4Exercise or conversion of a derivative
- May 5, 2022IFFSEC Form 4: Schultz Kare converted options into 1,089 shares, increasing direct ownership by 427% to 1,344 unitsForm 4Grant or awardExercise or conversion of a derivative
- Mar 5, 2022TEVASEC Form 4: Schultz Kare converted options into 293,586 units of Ordinary Shares, increasing direct ownership by 26% to 1,426,082 unitsForm 4Grant or awardExercise or conversion of a derivative
- Feb 28, 2022TEVASEC Form 4: Schultz Kare converted options into 65,047 units of Ordinary Shares, increasing direct ownership by 6% to 1,132,496 unitsForm 4Exercise or conversion of a derivative
- Feb 9, 2022TEVASEC Form 4: Schultz Kare converted options into 26,867 units of Ordinary Shares, increasing direct ownership by 3% to 1,067,449 unitsForm 4Grant or awardExercise or conversion of a derivative
- Nov 1, 2021TEVASEC Form 4: Schultz Kare converted options into 180,000 units of Ordinary Shares, increasing direct ownership by 21% to 1,040,582 unitsForm 4Exercise or conversion of a derivative
- May 6, 2021IFFSEC Form 4: Schultz Kare exercised 255 units of Common Stock at a strike of $0.00Form 4Grant or awardExercise or conversion of a derivative
- Mar 5, 2021TEVASEC Form 4: Kare Schultz exercised 59,701 units of Ordinary Shares at a strike of $0.00, increasing direct ownership by 7% to 860,582 unitsForm 4Grant or awardExercise or conversion of a derivative
- Mar 1, 2021IFFSEC Form 4 filed by Kare SchultzForm 4Grant or award
- Feb 28, 2021TEVASEC Form 4: Kare Schultz exercised 65,047 units of Ordinary Shares at a strike of $0.00, increasing ownership by 9% to 800,881 unitsForm 4Exercise or conversion of a derivative
- Feb 9, 2021TEVASEC Form 4: Kare Schultz exercised 26,867 units of Ordinary Shares at a strike of $0.00 and was granted 226,173 units of Ordinary Shares, increasing ownership by 52% to 735,834 unitsForm 4Grant or awardExercise or conversion of a derivative
- Feb 1, 2021IFFSEC Form 3 filed by Kare SchultzForm 3New insider
Compare Kare Schultz with
- Kare Schultz vs Oluyemi Okupe1 shared
- Kare Schultz vs Soleil Boughton1 shared
- Kare Schultz vs Deborah M. Autor1 shared
- Kare Schultz vs Christopher D Payne1 shared
- Kare Schultz vs Mohamed Elshenawy1 shared
- Kare Schultz vs Patrick Harrison Carroll1 shared
Other insiders at the same companies
- Deborah M. AutorHIMS
- Oluyemi OkupeHIMS
- Soleil BoughtonHIMS
- Christopher D PayneHIMS
- Mohamed ElshenawyHIMS
- Patrick Harrison CarrollHIMS
- Michael ChiHIMS
- David B WellsHIMS
- Andrew DudumHIMS
- Dov BergwerkTEVA
- Jonathan M FranklinHIMS
- Andrew D HubermanHIMS
- Winder Pte. Ltd.IFF
- Richard DaniellTEVA
- Richard D FrancisTEVA
- Mark SabagTEVA
Questions about Kare Schultz
- What is Kare Schultz's role at Teva Pharmaceutical Industries Ltd?
- Kare Schultz reports to the SEC as officer and director at Teva Pharmaceutical Industries Ltd (TEVA), according to the latest filing on November 2, 2022. Kare Schultz has also filed as director at Hims & Hers Health, Inc. (HIMS) and director at International Flavors & Fragrances Inc (IFF).
- How many shares does Kare Schultz own?
- After the latest filing that states it, Kare Schultz directly owned 26,020 shares of Hims & Hers Health, Inc. (HIMS), 1,542,471 shares of Teva Pharmaceutical Industries Ltd (TEVA) and 1,344 shares of International Flavors & Fragrances Inc (IFF). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Kare Schultz bought or sold stock recently?
- No open-market purchases or sales by Kare Schultz are on file. The filings report exercise or conversion of a derivative and grant or award.
- How do I get alerts when Kare Schultz files?
- Follow Kare Schultz on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Kare Schultz (SEC CIK 0001724567). Totals count each trade once, skipping amendments whose original is on file, from Feb 11, 2021 on. View on SEC EDGAR · Get this as JSON